Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29774271 | 0.86 | MAPT (0.61) | ALDH1A1GAAKDM4EMAPTCYP2C19 | |
| SCHEMBL20839691 | 0.83 | JAK3 (0.46) | HTTALDH1A1GAA | |
| SCHEMBL20839689 | 0.83 | JAK3 (0.46) | HTTALDH1A1GAA | |
| SCHEMBL18284918 | 0.82 | ALDH1A1 (0.51) | ALDH1A1 | |
| SCHEMBL18284920 | 0.82 | ALDH1A1 (0.51) | ALDH1A1 | |
| Lithium Ion SCHEMBL29774291 | 0.81 | CA12 (0.46) | HTTALDH1A1MAPT | |
| SCHEMBL29774313 | 0.81 | SMN1; SMN2 (0.46) | ALDH1A1GAAPOLBSMN1; SMN2 | |
| SCHEMBL6816668 | 0.79 | ALDH1A1 (0.63) | HTTALDH1A1GAAKDM4EMAPT | |
| SCHEMBL6816673 | 0.79 | ALDH1A1 (0.63) | HTTALDH1A1GAAKDM4EMAPT | |
| SCHEMBL18909691 | 0.78 | JAK3 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | UNIV NOTTINGHAM (GB) | 2022-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | CDK1, CDK11A, CDK12 | HTT 839/4885ALDH1A1 4568/4885GAA 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.